Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

CSL Behring: Clinical Trials & FDA Approval Profile

CSL Behring (Global / Institutional) sponsors 32 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 10 active protocols (9 recruiting now), 14 completed protocols, and 1 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)25.0%
Median Closed Enrollment vs National (145 pts)81 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for CSL Behring
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)32
Active Pipeline (Recruiting Now)10 (9)
Completed vs Stopped Early14 / 8 (25.0%)
Median Closed Actual Enrollment81 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals1 (1 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With CSL Behring
Hospital Research SiteLocationShared Protocols
University of Michigan Rogel Cancer CenterAnn Arbor, MI7
Vanderbilt University Medical CenterNashville, TN7
Duke University Medical CenterDurham, NC7

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by CSL Behring
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated VirusPhase IIIRECRUITING
NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe HePhase IIIRECRUITING
NCT07094087Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With CaPhase IIIRECRUITING
NCT05485961Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Phase II/IIIRECRUITING
NCT07648264Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting ChimePhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the CSL Behring Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI